IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023

IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023

Back

IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023

- 18 July 2023 - 1 mins read

Aggregated presentation by day and by market

Name of issuerIdentification code of issuer (Legal Entity Identifier)Day of transactionIdentification code of financial instrumentAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares *Market (MIC Code)
IPSEN549300M6SGDPB4Z94P1110/07/2023FR0010259150511108.65AQEU
IPSEN549300M6SGDPB4Z94P1110/07/2023FR00102591502,536108.53CEUX
IPSEN549300M6SGDPB4Z94P1110/07/2023FR0010259150507108.55TQEX
IPSEN549300M6SGDPB4Z94P1110/07/2023FR00102591505,255108.55XPAR
IPSEN549300M6SGDPB4Z94P1111/07/2023FR0010259150878109.08AQEU
IPSEN549300M6SGDPB4Z94P1111/07/2023FR00102591501,402108.94CEUX
IPSEN549300M6SGDPB4Z94P1111/07/2023FR0010259150633108.97TQEX
IPSEN549300M6SGDPB4Z94P1111/07/2023FR00102591505,387109.00XPAR
IPSEN549300M6SGDPB4Z94P1112/07/2023FR0010259150666108.65AQEU
IPSEN549300M6SGDPB4Z94P1112/07/2023FR00102591501,451108.65CEUX
IPSEN549300M6SGDPB4Z94P1112/07/2023FR0010259150782108.68TQEX
IPSEN549300M6SGDPB4Z94P1112/07/2023FR00102591503,640108.63XPAR
IPSEN549300M6SGDPB4Z94P1113/07/2023FR0010259150145110.02CEUX
IPSEN549300M6SGDPB4Z94P1113/07/2023FR0010259150790110.02XPAR
IPSEN549300M6SGDPB4Z94P1114/07/2023FR0010259150235110.67AQEU
IPSEN549300M6SGDPB4Z94P1114/07/2023FR0010259150242110.46CEUX
IPSEN549300M6SGDPB4Z94P1114/07/2023FR001025915065110.58TQEX
IPSEN549300M6SGDPB4Z94P1114/07/2023FR00102591501,358110.48XPAR
* Two-digit rounding after the decimalTOTAL26,483108.91

Attachment

Related Press Releases

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
11 July 2024 6 mins read

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
09 July 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
09 July 2024 1 mins read

Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Half-year statement of IPSEN liquidity agreement – 2024 06 30
08 July 2024 1 mins read

Half-year statement of IPSEN liquidity agreement – 2024 06 30
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
02 July 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
02 July 2024 9 mins read

Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
25 June 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
18 June 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
11 June 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
10 June 2024 12 mins read

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis